Search

Your search keyword '"Mahadevia PJ"' showing total 65 results

Search Constraints

Start Over You searched for: Author "Mahadevia PJ" Remove constraint Author: "Mahadevia PJ"
65 results on '"Mahadevia PJ"'

Search Results

1. Respiratory syncytial virus-related hospitalization in premature infants without bronchopulmonary dysplasia: subgroup efficacy analysis of the IMpact-RSV trial by gestational age group

Catalog

Books, media, physical & digital resources

13. Benefits and costs of immunizing children against influenza at school: an economic analysis based on a large-cluster controlled clinical trial.

14. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.

15. Risk factors for respiratory syncytial virus illness among patients with chronic obstructive pulmonary disease.

17. Systematic literature review assessing tobacco smoke exposure as a risk factor for serious respiratory syncytial virus disease among infants and young children.

18. Agreement between Internet-based self- and proxy-reported health care resource utilization and administrative health care claims.

19. Residential crowding and severe respiratory syncytial virus disease among infants and young children: a systematic literature review.

20. Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective.

21. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.

22. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.

23. A survey of children's preferences for influenza vaccine attributes.

24. Children's perceptions of influenza illness and preferences for influenza vaccine.

25. Parent preferences for pediatric influenza vaccine attributes.

26. Respiratory outcomes, utilization and costs 12 months following a respiratory syncytial virus diagnosis among commercially insured late-preterm infants.

27. The value of budget impact analyses in evaluating targeted therapies-The case of RSV prophylaxis for preterm infants.

28. Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infants.

29. Serious early childhood wheezing after respiratory syncytial virus lower respiratory tract illness in preterm infants.

30. Attending work while sick: implication of flexible sick leave policies.

31. Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children.

32. Employees' willingness to pay to prevent influenza.

33. Healthcare costs within a year of respiratory syncytial virus among Medicaid infants.

34. Parents' decision-making regarding vaccinating their children against influenza: A web-based survey.

35. Effect of influenza-like illness and other wintertime respiratory illnesses on worker productivity: The child and household influenza-illness and employee function (CHIEF) study.

36. Outpatient RSV lower respiratory infections among high-risk infants and other pediatric populations.

37. Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of life.

38. Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States.

39. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.

40. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention.

41. Persistence of morbidity and cost differences between late-preterm and term infants during the first year of life.

42. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.

43. Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres.

44. Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index.

45. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.

46. The pocketbook: Pharmacoeconomic issues related to intravenous immunoglobulin therapy.

47. Cost savings from intravenous immunoglobulin manufactured from chromotography/caprylate (IGIV-C) in persons with primary humoral immunodeficiency disorder.

48. Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: a conjoint analysis.

49. The epidemiology, treatment patterns, and costs of cytomegalovirus retinitis in the post-haart era among a national managed-care population.

50. Clinical management of primary hyperparathyroidism and thresholds for surgical referral: a national study examining concordance between practice patterns and consensus panel recommendations.